Dash Bio Secures $11M to Accelerate a New Era in Bioanalysis -- Bringing Total Funding to $17.5M
Summary
Dash Bio raised an additional $11 million, bringing total funding to $17.5 million. The company builds a highly automated, GLP-compliant bioanalysis platform for drug development. Its system speeds up assays such as ELISA, LC-MS, and qPCR and aims to replace slower, labor-intensive CRO workflows. The funding will support Dash Bio’s expansion as it works with biopharma customers and grows its team.
Funding
Amount
$11.0M
Total raised
Date
July 23, 2025
Announcement date
Investors
LifeX Ventures, Drive Capital, Freestyle Capital, Swift
Lead investors
Company
dashbio.com
Funded company
Classifications
industries
No industries detected
applications
No applications detected
AskAI Classifications
Labels
No AI classifications detected